EHP Funds Inc’s Moderna MRNA Stock Holding History

EHP Funds Inc’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-3,900	Closed	-$557K	–	424
2022 Q2	$557K	Sell	3,900 -400	-9%	-$57.2K	0.09%	146
2022 Q1	$741K	Buy	+4,300	New	+$724K	0.12%	146

Other funds holding MRNA

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return

Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

EHP Funds Inc's MRNA Position: Q3 2022 in Review

EHP Funds Inc sold out of Moderna (MRNA) in Q3 2022, closing a stake of 3,900 shares — an estimated $557K sold.

EHP Funds Inc first reported a position in MRNA in Q1 2022 and held it in 2 quarters. The position peaked at $741K in Q1 2022. 915 funds tracked by Wall St. Rank hold MRNA as of Q3 2022.

EHP Funds Inc reported no remaining Moderna position as of Q3 2022 after selling out during the quarter.
EHP Funds Inc sold 3,900 Moderna shares in Q3 2022, an estimated $557K.
EHP Funds Inc first reported a position in Moderna in Q1 2022 and held it in 2 quarters.
EHP Funds Inc's Moderna position peaked at $741K in Q1 2022.
915 funds tracked by Wall St. Rank held Moderna as of Q3 2022.

Based on EHP Funds Inc's 13F filing for Q3 2022, filed 14 Nov 2022.